Start
•
Completion

Psilocybin-Assisted Cognitive Processing Therapy for Chronic PTSD

Not yet recruitingRegisteredCTG

This open-label trial (n=15) will evaluate the feasibility, tolerability, safety, and efficacy of psilocybin-assisted (25mg) cognitive processing therapy for chronic Posttraumatic Stress Disorder (PTSD).

Details

Open-label, single-group Phase II study (n=15) evaluating a single 25 mg oral dose of psilocybin combined with 12 sessions of massed cognitive processing therapy (CPT) and two psilocybin-related psychotherapy sessions delivered over 7 days, with a 12-week follow-up.

Outcomes include feasibility, tolerability, safety, clinician-administered and self-report measures (e.g., CAPS-5), and continuous monitoring using a wearable device.

Topics:PTSD

Registry

Registry linkNCT06386003